Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dr Reddy's Laboratories has completely acquired GlaxoSmithKline's (GSK) US oral penicillin facility and product portfolio under an agreement signed between the companies in 2010.
Subscribe to our email newsletter
As per the terms of the agreement, GSK will transfer the ownership of penicillin manufacturing site in Bristol, Tennessee and the rights of Augmentin and Amoxil brands in the US to Dr Reddy‘s.
However, GSK will hold back the existing rights for Augmentin and Amoxil brands outside the US.
Augmentin and Amoxil are indicated for the treatment of bacterial infections.
The sale will allow GSK to concentrate resources on latest portfolio of differentiated products.
The acquisition is in line with Dr Reddy’s strategy to step up generics operations in North America while offering an opportunity to explore additional synergy with other businesses.